Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
SRF114 is designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment and has…